---
title: >-
  Impact of Therapeutic Inertia on Patient-Reported Outcomes in
  Moderate-to-Severe Atopic Dermatitis: A 12-Month Longitudinal Study from the
  TARGET-DERM AD Registry.
description: >-
  Explore this publication on real-world evidence: Impact of Therapeutic Inertia
  on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A…
date: '2023-01-01'
category: Publications
tags:
  - Care
  - Atopic Dermatitis (AD)
  - Health System Partner
  - Pharma Partner
  - Poster Presentation
  - R&D
  - RAD Conference
  - Dermatology
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/care/impact-of-therapeutic-inertia-on--2023-rad-conference/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: impact-of-therapeutic-inertia-on--2023-rad-conference
id: 6IhZTxtJGsK4nyoNrKErnt
contentType: article
---

## Challenge

This is a RAD Winter 2023 presentation of the same therapeutic inertia PRO study as Row 22 (Fall Clinical 2024). Earlier version of the analysis with the same core finding — a significant proportion of patients fail to achieve PRO targets with systemic therapy over 12 months without treatment escalation.

## Solution

TARGET-DERM AD registry used to track PRO trajectories in patients not meeting AHEAD targets at 3–12 months post-systemic therapy initiation, quantifying the patient-reported burden of therapeutic inertia.

## Impact

Multi-venue dissemination of the therapeutic inertia PRO findings broadens the evidence base for prescriber education and treatment escalation advocacy across key AD scientific communities.

### [Keith D. Knapp](/people/keith-knapp/)

### [Breda Munoz](/people/breda-munoz/)

![Breda Munoz, PhD — Profile Photo](https://images.ctfassets.net/h4s3ip99qawo/3H1T2mfvSNFj6w9tulnreq/a74ae05fe53e400f176d4e9c617b8fb8/breda-munoz.jpg)

### [Julie M. Crawford](/people/julie-crawford/)